PHVS vs RILYP Comparison

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services, telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across various business lines. The Group has seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Capital Markets segment, which provides investment banking and institutional brokerage services, offers loans, trades in equity securities, and maintains an investment portfolio of public and private equities and debt securities. Geographically, the Group derives maximum revenue from its business in North America.